International law firm McDermott Will & Emery represented Pasithea Therapeutics Corp. (Pasithea), a US biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, in its acquisition of Alpha-5 Integrin, LLC (Alpha-5), a privately-held preclinical-stage company developing a monoclonal antibody (mAbs) for the treatment of amyotrophic lateral sclerosis and other neuroinflammatory disorders, such as multiple sclerosis.
Pasithea acquired all of Alpha-5’s issued and outstanding equity interests in exchange for 3,260,870 shares of Pasithea common stock plus warrants to acquire an additional 1,000,000 shares. The acquisition includes potential future earnouts based on net sales.
The McDermott team was led by Bob Cohen and Eric Klee and included Graciany Miranda, Jeronimo Soares de Sousa, Dan Zucker, Michael Siekman, Rodney Swartz, Todd Solomon, Evan Belosa, Nick Paul, David Saunders, Michelle Stowhiro, Abigail Kagan, Richard Bass and Brandon Sloane.
Read Pasithea’s press release here.
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices, industries and more than 20 locations to deliver highly effective solutions that propel success. More than 1,200 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.
Kerri Chace+1 617 535 4145